HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE).

AbstractBACKGROUND:
Ambient air pollution is suspected to cause lung cancer. We aimed to assess the association between long-term exposure to ambient air pollution and lung cancer incidence in European populations.
METHODS:
This prospective analysis of data obtained by the European Study of Cohorts for Air Pollution Effects used data from 17 cohort studies based in nine European countries. Baseline addresses were geocoded and we assessed air pollution by land-use regression models for particulate matter (PM) with diameter of less than 10 μm (PM10), less than 2·5 μm (PM2·5), and between 2·5 and 10 μm (PMcoarse), soot (PM2·5absorbance), nitrogen oxides, and two traffic indicators. We used Cox regression models with adjustment for potential confounders for cohort-specific analyses and random effects models for meta-analyses.
FINDINGS:
The 312 944 cohort members contributed 4 013 131 person-years at risk. During follow-up (mean 12·8 years), 2095 incident lung cancer cases were diagnosed. The meta-analyses showed a statistically significant association between risk for lung cancer and PM10 (hazard ratio [HR] 1·22 [95% CI 1·03-1·45] per 10 μg/m(3)). For PM2·5 the HR was 1·18 (0·96-1·46) per 5 μg/m(3). The same increments of PM10 and PM2·5 were associated with HRs for adenocarcinomas of the lung of 1·51 (1·10-2·08) and 1·55 (1·05-2·29), respectively. An increase in road traffic of 4000 vehicle-km per day within 100 m of the residence was associated with an HR for lung cancer of 1·09 (0·99-1·21). The results showed no association between lung cancer and nitrogen oxides concentration (HR 1·01 [0·95-1·07] per 20 μg/m(3)) or traffic intensity on the nearest street (HR 1·00 [0·97-1·04] per 5000 vehicles per day).
INTERPRETATION:
Particulate matter air pollution contributes to lung cancer incidence in Europe.
FUNDING:
European Community's Seventh Framework Programme.
AuthorsOle Raaschou-Nielsen, Zorana J Andersen, Rob Beelen, Evangelia Samoli, Massimo Stafoggia, Gudrun Weinmayr, Barbara Hoffmann, Paul Fischer, Mark J Nieuwenhuijsen, Bert Brunekreef, Wei W Xun, Klea Katsouyanni, Konstantina Dimakopoulou, Johan Sommar, Bertil Forsberg, Lars Modig, Anna Oudin, Bente Oftedal, Per E Schwarze, Per Nafstad, Ulf De Faire, Nancy L Pedersen, Claes-Göran Ostenson, Laura Fratiglioni, Johanna Penell, Michal Korek, Göran Pershagen, Kirsten T Eriksen, Mette Sørensen, Anne Tjønneland, Thomas Ellermann, Marloes Eeftens, Petra H Peeters, Kees Meliefste, Meng Wang, Bas Bueno-de-Mesquita, Timothy J Key, Kees de Hoogh, Hans Concin, Gabriele Nagel, Alice Vilier, Sara Grioni, Vittorio Krogh, Ming-Yi Tsai, Fulvio Ricceri, Carlotta Sacerdote, Claudia Galassi, Enrica Migliore, Andrea Ranzi, Giulia Cesaroni, Chiara Badaloni, Francesco Forastiere, Ibon Tamayo, Pilar Amiano, Miren Dorronsoro, Antonia Trichopoulou, Christina Bamia, Paolo Vineis, Gerard Hoek
JournalThe Lancet. Oncology (Lancet Oncol) Vol. 14 Issue 9 Pg. 813-22 (Aug 2013) ISSN: 1474-5488 [Electronic] England
PMID23849838 (Publication Type: Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2013 Elsevier Ltd. All rights reserved.
Chemical References
  • Particulate Matter
Topics
  • Adenocarcinoma (epidemiology, etiology)
  • Adult
  • Aged
  • Air Pollution (adverse effects)
  • Carcinoma, Squamous Cell (epidemiology, etiology)
  • Environmental Exposure
  • Europe (epidemiology)
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Lung Neoplasms (epidemiology, etiology)
  • Male
  • Middle Aged
  • Particulate Matter (adverse effects)
  • Prognosis
  • Prospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: